Sandor Victor 4

What Happened

• Sandor Victor, a director of Kymera Therapeutics (KYMR), received an award on 2026-06-24 consisting of 6,068 derivative shares (stock option/award) reported at $0.00 per share. This was an award/acquisition (Transaction code A) and did not generate immediate proceeds.

Key Details

• Transaction date: 2026-06-24; Form 4 filed 2026-06-25 (timely filing).
• Award: 6,068 derivative shares/options at $0.00 per share (reported as a derivative acquisition).
• Shares owned after transaction: Not disclosed in the Form 4.
• Footnote: The shares underlying this stock option vest in full upon the earlier of (i) June 24, 2027 and (ii) the date of the next annual meeting of stockholders (see F1).
• No indication of an immediate sale or cashless exercise in the filing.

Context

• This was a forward-looking equity award (options/derivative) that vests in the future; it does not represent an immediate sale or cash proceeds. Director awards are commonly part of compensation and should be viewed as an acquisition of potential future equity rather than an immediate purchase or monetization.